Previous 10 | Next 10 |
Affimed N.V. (NASDAQ: AFMD ) has been added to the Russell 2000, Russell 3000, and Russell Microcap Indexes, effective after the U.S. markets closed on Friday, June 28, 2019. More news on: Affimed N.V., Axsome Therapeutics, Inc., EyePoint Pharmaceuticals, Inc., Healthcare stocks new...
Heidelberg, Germany, July 1, 2019 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that it has been added to the Russell 2000 ® , Russell 3000 ® , and Russel...
Gainers: VivoPower International (NASDAQ: VVPR ) +108% . Minerva Neurosciences (NASDAQ: NERV ) +43% . PCM (NASDAQ: PCMI ) +42% . Krystal Biotech (NASDAQ: KRYS ) +30% . NRC Group Holdings (NYSEMKT: NRCG ) +26% . India Globalization Capital (NYSEMKT: IGC ) +21% . Rekor Systems (R...
Affimed ( AFMD -12% ) slumps on average volume in response to updated results on lead candidate AFM13 in patients with CD30-positive lymphomas. The data were presented at the International Conference on Malignant Lymphoma in Lugano, Switzerland. More news on: Affimed N.V., Merck &...
Heidelberg, Germany, June 24, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced the presentation of data updates on two clinical studies at the 15 th Internatio...
Melinta Therapeutics (NASDAQ: MLNT ) +98% on FDA approval of BAXDELA sNDA. More news on: Melinta Therapeutics, Inc., MYOS RENS Technology Inc., Axalta Coating Systems Ltd., Stocks on the move, Read more ...
Heidelberg, Germany, June 12, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, announced today that two abstracts from the Company’s lead innate cell engager AFM13...
Heidelberg, Germany, June 04, 2019 – Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancers, announced today that the Annual General Meeting of Shareholders will be held on Tuesday, June 25...
Tartu (Estonia) and Plzen (Czech Republic) June 3, 2019 - Icosagen Cell Factory OÜ, a rapidly growing Estonian biotechnology company focusing on protein production and in vivo antibody discovery, and AbCheck s.r.o., a leader in providing antibody drug discover...
Heidelberg, Germany, May 29, 2019 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced that its Chief Executive Officer, Dr. Adi Hoess, will present at the Jefferies 2019 Healthcar...
News, Short Squeeze, Breakout and More Instantly...
Affimed N.V. Company Name:
AFMD Stock Symbol:
NASDAQ Market:
The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR wild-type non-small cell lung cancer have been accepted for poster presentation MANNHEIM, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- Affimed N....
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...
AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer (NSCLC) EGFR -wildtype cohort: one complete response (CR), three partial responses (PR), and seven stable disease patients in the 15 heavily p...